Business
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis
WILMINGTON, Del., May 07, 2026--Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs). These data were presented (Abstract ID: P0851) today at the 2026 European Academy of Dermatology and Venereology (EADV) Symp
About this update from Incyte Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":349,"url":"https://media.zenfs.com/en/business-wire.com/ef5a9d2116dbb5d34615f61b8fc22e41"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/aA.DHmpYM.H6X5.YkdmA4g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY5OA--/https://media.zenfs.com/en/business-wire.com/ef5a9d2116dbb5d34615f61b8fc22e41","width":480,"height":349},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/.6tLIURbEVXyuIKgnvwlyA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTQ2NQ--/https://media.zenfs.com/en/business-wire.com/ef5a9d2116dbb5d34615f61b8fc22e41","width":480,"height":349}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) at the 2026 EADV Symposium","length":271,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The vast majority of patients achieving EASI50 at Week 8 and continuing double-blind, as needed treatment with Opzelura® (ruxolitinib) cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 (a ≥75% improvement in the Eczema Area and Severity Index score from baseline) and 70.6% achieving IGA-TS (Investigator’s Global Assessment Treatment Success)","length":373,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Data support Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU), feedback expected in 1H 2026","length":181,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":825,"olType":false},{"type":"text","content":"WILMINGTON, Del., May 07, 2026--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs). These data were presented (Abstract ID: P0851) today at the 2026 European Academy of Dermatology and Ve...